- Celonic Group and CARBOGEN AMCIS have formed a strategic partnership to provide fully integrated development and manufacturing for antibody-drug conjugates (ADCs), covering the entire process from cell line development to commercial fill-finish.
- The collaboration combines Celonic’s biologics expertise with CARBOGEN AMCIS’s capabilities in payload synthesis, conjugation, and sterile manufacturing, offering a single accountable partner for ADC innovators.
Celonic Group, a biologics CDMO, has partnered with CARBOGEN AMCIS, a pharmaceutical process development and API manufacturing company, to offer an end-to-end solution for antibody-drug conjugate (ADC) development and manufacturing. The alliance integrates Celonic’s advanced biologics platforms with CARBOGEN AMCIS’s payload, linker, conjugation, and sterile fill-finish expertise.
The partnership is designed to streamline the ADC supply chain, accelerate timelines, and support clients from early-stage development through commercial launch. Celonic recently expanded its Biologics Development Center in Basel and GMP manufacturing site in Heidelberg, adding high-yield GS-CHOvolution™ cell line capabilities and commercial-scale biomanufacturing suites. CARBOGEN AMCIS has provided ADC services since 2005 and operates dedicated conjugation suites in Switzerland and a commercial sterile manufacturing facility in France.
“This strategic alliance is a direct response to the evolving needs of ADC innovators. By integrating Celonic’s advanced biologics platforms with CARBOGEN AMCIS’s world-class payload and conjugation capabilities, we’re enabling a fully harmonised development and manufacturing pathway, from DNA to drug product.”
Dr. Samanta Cimitan, CEO of Celonic Group
The integrated offering covers cell line development and antibody production (Celonic), payload and linker synthesis (CARBOGEN AMCIS), ADC conjugation and sterile fill-finish (CARBOGEN AMCIS), and regulatory support, including CMC documentation for IND, IMPD, and BLA filings. This approach allows clients to work with a single accountable partner, reducing variability and handoffs.
“Together, we offer a comprehensive service for ADC development, streamlined, scalable, and globally compliant.” The partnership aims to meet growing demand for targeted cancer therapies by combining technical expertise, operational agility, and global compliance in contract manufacturing.
Stephan Fritschi, CEO of CARBOGEN AMCIS
